This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ironwood's (IRWD) Q2 Earnings Beat, 2021 Guidance Raised
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. Stock up.
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) earnings and revenues beat estimates in the second quarter of 2021. The company raised its financial guidance for 2021.
Aerie's(AERI) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Aerie (AERI) incurs wider-than-expected loss in the second quarter of 2021 but sales beat expectations.
Why Ironwood (IRWD) Could Beat Earnings Estimates Again
by Zacks Equity Research
Ironwood (IRWD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Athira (ATHA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus to be on the company's pipeline progress, mainly on its small molecule candidate ATH-1017 for Alzheimer's disease, on Athira's (ATHA) second-quarter earnings call.
Bausch's (BHC) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the second quarter. The company also lowers its annual revenue guidance.
Pacira's (PCRX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings and revenues in the second quarter of 2021 surpass estimates. Exparel sales surge year over year.
Jazz Pharma (JAZZ) Q2 Earnings Beat, Sales Ride on GW Buyout
by Zacks Equity Research
Jazz Pharma's (JAZZ) product revenues grow in the second quarter on the back of strong demand for its new drugs and additional sales from drugs added with the acquisition of GW Pharmaceuticals.
Esperion (ESPR) Q2 Loss Narrower Than Expected, Drug Price Up
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings but misses the same for sales. Stock down.
AMN Healthcare (AMN) to Report Q2 Earnings: What to Expect?
by Zacks Equity Research
Continued strength in AMN Healthcare's (AMN) staffing services is expected to have driven up Q2 sales.
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q2 results.
Ocugen (OCGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is likely to provide updates related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports second-quarter 2021 results.
What's in Store for Senseonics Holdings' (SENS) Q2 Earnings?
by Zacks Equity Research
Senseonics Holdings' (SENS) second-quarter results are likely to gain from higher sales outside the United States.
DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect strong segmental performance.
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment is expected to have driven up Q3 sales.
Will Eylea & Dupixent Drive Regeneron's (REGN) Q2 Earnings?
by Zacks Equity Research
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2021 results.
Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2
by Ekta Bagri
We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.
Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q1 sales.
Ironwood (IRWD) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Ironwood (IRWD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Incyte (INCY) to Post Q2 Earnings: Will Jakafi Sales Disappoint?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports second-quarter 2021 results.
Gilead (GILD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports second-quarter 2021 results.
Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vaxart's (VXRT) second-quarter earnings call, investors are set to mainly focus on updates on the company's progress with oral vaccine candidates for COVID-19 and Norovirus.